MTEM Stock Overview
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases.
Molecular Templates Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.06|
|52 Week High||US$8.62|
|52 Week Low||US$0.76|
|1 Month Change||9.12%|
|3 Month Change||-60.15%|
|1 Year Change||-87.38%|
|3 Year Change||-87.30%|
|5 Year Change||n/a|
|Change since IPO||-82.33%|
Recent News & Updates
Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|MTEM||US Biotechs||US Market|
Return vs Industry: MTEM underperformed the US Biotechs industry which returned -24.4% over the past year.
Return vs Market: MTEM underperformed the US Market which returned -18.5% over the past year.
|MTEM Average Weekly Movement||15.1%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: MTEM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: MTEM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients.
Molecular Templates Fundamentals Summary
|MTEM fundamental statistics|
Is MTEM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MTEM income statement (TTM)|
|Cost of Revenue||US$84.79m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.38|
|Net Profit Margin||-177.06%|
How did MTEM perform over the long term?See historical performance and comparison
Is MTEM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MTEM?
Other financial metrics that can be useful for relative valuation.
|What is MTEM's n/a Ratio?|
Price to Sales Ratio vs Peers
How does MTEM's PS Ratio compare to its peers?
|MTEM PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: MTEM is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (9x).
Price to Earnings Ratio vs Industry
How does MTEM's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Sales vs Industry: MTEM is good value based on its Price-To-Sales Ratio (1.4x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is MTEM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.4x|
|Fair PS Ratio||0.9x|
Price-To-Sales vs Fair Ratio: MTEM is expensive based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).
Share Price vs Fair Value
What is the Fair Price of MTEM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MTEM's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MTEM's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MTEM's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Molecular Templates forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MTEM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MTEM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MTEM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MTEM's revenue (25.1% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: MTEM's revenue (25.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MTEM's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Molecular Templates performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MTEM is currently unprofitable.
Growing Profit Margin: MTEM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MTEM is unprofitable, and losses have increased over the past 5 years at a rate of 34.3% per year.
Accelerating Growth: Unable to compare MTEM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTEM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: MTEM has a negative Return on Equity (-163.94%), as it is currently unprofitable.
Discover strong past performing companies
How is Molecular Templates's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MTEM's short term assets ($132.4M) exceed its short term liabilities ($45.0M).
Long Term Liabilities: MTEM's short term assets ($132.4M) exceed its long term liabilities ($70.7M).
Debt to Equity History and Analysis
Debt Level: MTEM has more cash than its total debt.
Reducing Debt: MTEM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MTEM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MTEM has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 32.8% each year.
Discover healthy companies
What is Molecular Templates's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MTEM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MTEM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MTEM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MTEM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MTEM has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Eric Poma (49 yo)
Dr. Eric E. Poma, Ph D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as its President. Dr. Poma founded Private Molecular in February 2009...
CEO Compensation Analysis
Compensation vs Market: Eric's total compensation ($USD4.38M) is above average for companies of similar size in the US market ($USD752.25K).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
Experienced Management: MTEM's management team is seasoned and experienced (7.9 years average tenure).
Experienced Board: MTEM's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MTEM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Molecular Templates, Inc.'s employee growth, exchange listings and data sources
- Name: Molecular Templates, Inc.
- Ticker: MTEM
- Exchange: NasdaqGS
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$59.720m
- Shares outstanding: 56.34m
- Website: https://www.mtem.com
Number of Employees
- Molecular Templates, Inc.
- 9301 Amberglen Boulevard
- Suite 100
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.